BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+3.35%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$17.4B
AUM Growth
+$17.4B
(+0.42%)
Cap. Flow
-$153M
Cap. Flow
% of AUM
-0.88%
Top 10 Holdings %
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
16
Reduced
13
Closed
14
Top Buys
| 1 |
Roivant Sciences
ROIV
|
$28.6M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$20.8M |
| 3 |
AbCellera Biologics
ABCL
|
$19.8M |
| 4 |
Denali Therapeutics
DNLI
|
$17.3M |
| 5 |
Immunovant
IMVT
|
$16.3M |
Top Sells
| 1 |
argenx
ARGX
|
$63.4M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$55.9M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$48.1M |
| 4 |
TLIS
Talis Biomedical Corporation Common Stock
TLIS
|
$41.1M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
$28.7M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.45B | 54.48% | 44,554,162 | – | – |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $2.1B | 12.1% | 11,668,897 | – | – |
|
3
Incyte
INCY
$16.5B
| $2.09B | 12.05% | 36,178,566 +510 | +0% | +$29.5K |
|
4
Acadia Pharmaceuticals
ACAD
$4.38B
| $893M | 5.15% | 42,864,612 | – | – |
|
5
BioMarin Pharmaceuticals
BMRN
$11.2B
| $337M | 1.94% | 3,810,248 | – | – |
|
6
Madrigal Pharmaceuticals
MDGL
$9.76B
| $226M | 1.3% | 1,545,113 | – | – |
|
7
Rhythm Pharmaceuticals
RYTM
$6.85B
| $154M | 0.89% | 6,702,349 +204,082 | +3% | +$4.68M |
|
|
8
Roivant Sciences
ROIV
$8.15B
| $139M | 0.8% | 11,877,171 +2,448,579 | +26% | +$28.6M |
|
9
Immunocore
IMCR
$1.62B
| $131M | 0.75% | 2,520,731 | – | – |
|
10
Akero Therapeutics
AKRO
$3.74B
| $120M | 0.69% | 2,368,378 | – | – |
|
|
11
AbCellera Biologics
ABCL
$1.25B
| $95.5M | 0.55% | 20,763,323 +4,313,143 | +26% | +$19.8M |
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $90M | 0.52% | 12,710,818 | – | – |
|
13
Replimune Group
REPL
$422M
| $78.3M | 0.45% | 4,578,280 | – | – |
|
14
Entrada Therapeutics
TRDA
$208M
| $76.9M | 0.44% | 4,865,819 | – | – |
|
15
Revolution Medicines
RVMD
$7.1B
| $74.5M | 0.43% | 2,691,493 | – | – |
|
|
16
argenx
ARGX
$43.6B
| $74.3M | 0.43% | 151,215 -128,944 | -46% | -$63.4M |
|
|
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
| $69.4M | 0.4% | 2,999,846 | – | – |
|
18
Kymera Therapeutics
KYMR
$2.95B
| $66M | 0.38% | 4,750,400 +375,060 | +9% | +$5.21M |
|
19
Immatics
IMTX
$619M
| $65.3M | 0.38% | 5,640,816 | – | – |
|
|
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $61.4M | 0.35% | 1,409,784 | – | – |
|
21
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $48.8M | 0.28% | 2,809,577 | – | – |
|
|
22
Ultragenyx Pharmaceutical
RARE
$2.89B
| $48.7M | 0.28% | 1,366,547 +583,488 | +75% | +$20.8M |
|
|
23
Denali Therapeutics
DNLI
$2.23B
| $47.3M | 0.27% | 2,292,003 +836,681 | +57% | +$17.3M |
|
24
Prelude Therapeutics
PRLD
$68.5M
| $31.3M | 0.18% | 10,123,824 | – | – |
|
25
Kodiak Sciences
KOD
$478M
| $31.2M | 0.18% | 17,310,490 | – | – |
|